Medicus Pharma Ltd. (MDCX) Stock Price & Analysis
Medicus Pharma Ltd. (MDCX) fell 4.02% to USD 0.32 as of June 10, 2026 at 07:19 UTC, according to Nexqual real-time market data.
MDCX last closed at USD 0.34; the session ranged USD 0.32–0.34 on volume of 863,638 shares. Market capitalization is $18.28M, with a 52-week range of USD 0.25–3.69 (NCM). Source: Nexqual, June 10, 2026 at 07:19 UTC.
Key Statistics (as of June 10, 2026 at 07:19 UTC)
| Price | USD 0.32 |
|---|---|
| Change | ▼ 4.02% (down) |
| Previous Close | USD 0.34 |
| Open | USD 0.34 |
| Day Range | USD 0.32 – 0.34 |
| 52-Week Range | USD 0.25 – 3.69 |
| Volume | 863,638 shares |
| Market Cap | $18.28M |
| Exchange | NCM |
Technical Analysis (MDCX)
Nexqual's technical model rates MDCX "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 07:19 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.35 (neutral) |
| vs SMA50 | Below (USD 0.35) |
| MACD | -0 (negative) |
Analyst Ratings (MDCX)
Wall Street analysts rate MDCX "Strong Buy" based on 3 analysts, with a mean price target of USD 5.67 (range USD 2–9), per Nexqual as of June 10, 2026 at 07:19 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 5.67 |
| High Target | USD 9 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (MDCX)
| EPS Estimate | USD -0.16 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.3 vs est -0.22 ▼ miss |
| 2025-12-31 | USD -0.44 vs est -0.29 ▼ miss |
| 2025-09-30 | USD -1.09 vs est -0.38 ▼ miss |
| 2025-06-30 | USD -0.42 vs est -0.27 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Financials & Fundamentals (MDCX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -2865.18% |
| Debt / Equity | 177.5 |
| Current Ratio | 1.22 |
| Total Cash | $6.37M |
| Total Debt | $2.53M |
| Free Cash Flow | $-16.49M |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Financial Health Score (MDCX)
Nexqual rates Medicus Pharma Ltd.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $6M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$28M |
| Efficiency | Critical — ROE -2865%, ROA -278.1% |
Ownership (MDCX)
| Insider Ownership | +12.83% |
|---|---|
| Institutional Ownership | +4.10% |
| Shares Outstanding | 56.66M |
| Float | 50.14M |
| Short % of Float | +5.56% |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Leadership (MDCX)
Medicus Pharma Ltd. is led by Raza Bokhari (age 57), CEO & Executive Chairman, per Nexqual as of June 10, 2026 at 07:19 UTC.
| CEO & Executive Chairman | Raza Bokhari (age 57) |
|---|---|
| Chief Scientific Officer and Head of R & D Program | Edward J. Brennan Jr., F.A.C.S. (age 64) |
| Chief Operating Officer | Andrew Alasdair Smith (age 56) |
| Senior Vice President of Investor Relations | Anna Baran-Djokovic |
| Senior Vice President of Public Relations | Viktoria Slepeniuk |
Major Backers & Investors (MDCX)
Notable institutional backers of Medicus Pharma Ltd. include Interchange Capital Partners, LLC, Private Advisor Group, LLC, Virtu Financial LLC, according to Nexqual as of June 10, 2026 at 07:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Interchange Capital Partners, LLC | 2.93% |
| Private Advisor Group, LLC | 0.42% |
| Virtu Financial LLC | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.13% |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
From Medicus Pharma Ltd.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States.
- It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
- The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BNZI | Banzai International, Inc. | USD 3.11 | ▲ 3.32% |
| FMST | Foremost Clean Energy Ltd. | USD 1.49 | ▼ 0.67% |
| SAFX | XCF Global, Inc. | USD 0.37 | ▼ 7.96% |
| VWAV | VisionWave Holdings, Inc. | USD 5.15 | ▼ 1.72% |
| MAIA | MAIA Biotechnology, Inc. | USD 1.3 | ▼ 4.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:19 UTC. This page is informational and not investment advice.